Pharmacology Shared Resource

Mayo Clinic Rochester, Rochester MN

Investigators

Linked publications & trials

Abstract

PHARMACOLOGY SHARED RESOURCE: ABSTRACT The development of successful cancer therapies critically depends on a thorough understanding of the physicochemical properties of investigational agents, precise and sensitive analytical methods, well-planned and ethical investigations of pharmacokinetics and pharmacodynamics in animals and humans, and a team of experienced and well-trained professional and technical staff. The long-term objective of the Pharmacology Shared Resource (PHMSR) is to provide critical pharmacologic support, services, and expertise for members of the Mayo Clinic Comprehensive Cancer Center (MCCCC) who are engaged in developing and evaluating novel therapeutic modalities in the treatment of cancer. PHMSR will achieve this objective through three Specific Aims: Aim 1: Conduct clinical pharmacokinetic, pharmacodynamic and pharmacogenetic studies for members of the MCCCC and the Experimental and Novel Therapeutics Disease Group. Aim 2: Conduct preclinical pharmacology studies in support of MCCCC investigator-initiated research and novel drug development. Aim 3: Develop and incorporate pharmacometric approaches for preclinical and clinical pharmacology studies conducted by MCCCC investigators. PHMSR provides clinical pharmacologic expertise, methodologies, services, and support for investigator- initiated research by MCCCC members. This includes robust analytical methodologies to measure drugs and metabolites in biological matrices, methods to study drug metabolism and identify metabolites, pharmacokinetic and pharmacodynamic modeling and simulation, pharmacogenetic methods to assess genetic variations in drug response, and basic pharmacologic methodologies. Examples include consultation and pharmacologic support to basic scientists collecting preliminary pharmacologic data for grant applications, investigators who have pharmacologic aims in their grants or wish to pursue leads with potentially druggable targets, and clinician investigators who do not have their own laboratory programs. MCCCC members represent the majority of users (mean of 65% over the current funding period) and of revenue (mean of 73%). Since 2019, PHMSR has supported MCCCC investigators with the publication of 29 articles. Member Utilization 2019-2023: 56 Total (1 CPCS, 5 REDI, 4 CGSM, 4 CII, 19 NTTM, 23 ACTS) Publication by Members: 29, 5 with Impact Factor >10